Type 2 diabetes mellitus
Conditions
Interventions
Test group: 10mg of Henagliflozin,Qd
Control group:Primary hypoglycemic background drugs (non-SGLT2I OADs)
Sponsors
The Affiliated Hospital Of Qingdao University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. 18 years old = the age of T2DM =75 years old 2. 7.0%=HbA1c=11.0% 3. Combined with hyperuricemia, as defined in the Chinese Guidelines for Diagnosis and Treatment of Hyperuricemia and Gout (2019) 4.Patients with or without gout, and non-acute gout 5. sign the informed consent form
Exclusion criteria
Exclusion criteria: 1. patients allergic to Henagliflozin 2. patients diagnosed with secondary gout 3. Taking drugs that affect uric acid metabolism in the blood, such as atorvastatin, losartan, dihydrocrethiazide, furosemide, riuric acid, pyrazinamide, low-dose aspirin, etc., and drugs containing the above ingredients, such as compound antihypertensive tablets; Or had taken glucocorticoids within 1 month before enrollment; Use of non-steroidal anti-inflammatory drugs or other pain medications in the 48 hours prior to baseline evaluation 4. Xanthinuria patients 5. Patients with severe hypertriglyceridemia 6. Patients with severe cardiovascular and cerebrovascular diseases 7. Joint disease caused by rheumatoid arthritis and other causes requiring treatment 8. Type 1 diabetes 9. T2DM with a history of ketoacidosis (DKA) 10. eGFR < 30 mL/min/1.73 m2 11. Currently using or having used SGLT2i drugs within 3 months 12. Patients with diagnosed malignant tumors 13. Pregnant and lactating women and women of childbearing age who do not want to use reliable contraception 14. Patients participating in other clinical trials within 3 months 15. According to the investigators' judgment, the patient had other conditions that were not suitable for enrollment 16. In addition to the above, the investigators judged that the patients were not suitable to participate in this clinical trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| change of serum uric acid from baseline in each group; | — |
Secondary
| Measure | Time frame |
|---|---|
| HbA1c;UACR; | — |
Countries
China
Contacts
Public ContactWang Yangang
The Affiliated Hospital Of Qingdao University
Outcome results
None listed